Direct-to-Lymph node cancer treatment tested in early trial
NCT ID NCT05393713
Summary
This early-phase study tested the safety and best dose of an immunotherapy drug called STI-3031. The drug was delivered directly into the lymph vessels or nodes of a single limb using a special device, aiming to treat melanoma that had spread locally. The goal was to see if this targeted delivery method was feasible and could help the immune system fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.